These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 17699395)

  • 1. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
    Torres VE; King BF; Chapman AB; Brummer ME; Bae KT; Glockner JF; Arya K; Risk D; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Meyers CM; Zhang X; Thompson PA; Miller JP;
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):112-20. PubMed ID: 17699395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort.
    Rule AD; Torres VE; Chapman AB; Grantham JJ; Guay-Woodford LM; Bae KT; Klahr S; Bennett WM; Meyers CM; Thompson PA; Miller JP;
    J Am Soc Nephrol; 2006 Mar; 17(3):854-62. PubMed ID: 16452494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.
    King BF; Torres VE; Brummer ME; Chapman AB; Bae KT; Glockner JF; Arya K; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
    Kidney Int; 2003 Dec; 64(6):2214-21. PubMed ID: 14633145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study.
    Fick-Brosnahan GM; Belz MM; McFann KK; Johnson AM; Schrier RW
    Am J Kidney Dis; 2002 Jun; 39(6):1127-34. PubMed ID: 12046022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
    Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
    Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlations between renal function and the total kidney volume measured on imaging for autosomal dominant polycystic kidney disease: A systematic review and meta-analysis.
    Jo WR; Kim SH; Kim KW; Suh CH; Kim JK; Kim H; Lee JG; Oh WY; Choi SE; Pyo J
    Eur J Radiol; 2017 Oct; 95():56-65. PubMed ID: 28987699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoregulation of renal blood flow and pressure-dependent renin release in autosomal dominant polycystic kidney disease of rats.
    Braun C; Lüdicke C; Rebsch W; Gretz N; van der Woude FJ; Rohmeiss P
    Nephrol Dial Transplant; 1996; 11 Suppl 6():52-7. PubMed ID: 9044329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Blood pressure, functional and morphological study of kidneys in children with autosomal dominant polycystic kidney disease].
    Seeman T; Vondrichová H; Strízová J; Sikut M; Janda J; Schärer K
    Cas Lek Cesk; 1999 Mar; 138(6):178-84. PubMed ID: 10510532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.
    Bae KT; Zhu F; Chapman AB; Torres VE; Grantham JJ; Guay-Woodford LM; Baumgarten DA; King BF; Wetzel LH; Kenney PJ; Brummer ME; Bennett WM; Klahr S; Meyers CM; Zhang X; Thompson PA; Miller JP;
    Clin J Am Soc Nephrol; 2006 Jan; 1(1):64-9. PubMed ID: 17699192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.
    Torres VE; Grantham JJ; Chapman AB; Mrug M; Bae KT; King BF; Wetzel LH; Martin D; Lockhart ME; Bennett WM; Moxey-Mims M; Abebe KZ; Lin Y; Bost JE;
    Clin J Am Soc Nephrol; 2011 Mar; 6(3):640-7. PubMed ID: 21088290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M; Inci A
    Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Schrier RW
    J Am Soc Nephrol; 2009 Sep; 20(9):1888-93. PubMed ID: 19696226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
    Uchiyama K; Mochizuki T; Shimada Y; Nishio S; Kataoka H; Mitobe M; Tsuchiya K; Hanaoka K; Ubara Y; Suwabe T; Sekine A; Nutahara K; Tsuruya K; Ishimura E; Nakatani S; Sofue T; Tanaka S; Narita I; Maruyama S; Horie S; Muto S
    Clin Exp Nephrol; 2021 Sep; 25(9):970-980. PubMed ID: 33928479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
    Higashihara E; Torres VE; Chapman AB; Grantham JJ; Bae K; Watnick TJ; Horie S; Nutahara K; Ouyang J; Krasa HB; Czerwiec FS;
    Clin J Am Soc Nephrol; 2011 Oct; 6(10):2499-507. PubMed ID: 21903984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney volume and function in autosomal dominant polycystic kidney disease.
    Higashihara E; Nutahara K; Okegawa T; Shishido T; Tanbo M; Kobayasi K; Nitadori T
    Clin Exp Nephrol; 2014 Feb; 18(1):157-65. PubMed ID: 23864346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
    Chapman AB; Bost JE; Torres VE; Guay-Woodford L; Bae KT; Landsittel D; Li J; King BF; Martin D; Wetzel LH; Lockhart ME; Harris PC; Moxey-Mims M; Flessner M; Bennett WM; Grantham JJ
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):479-86. PubMed ID: 22344503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
    Irazabal MV; Torres VE; Hogan MC; Glockner J; King BF; Ofstie TG; Krasa HB; Ouyang J; Czerwiec FS
    Kidney Int; 2011 Aug; 80(3):295-301. PubMed ID: 21544064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
    Kim K; Trott JF; Gao G; Chapman A; Weiss RH
    BMC Nephrol; 2019 Feb; 20(1):66. PubMed ID: 30803434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.